These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30577309)

  • 1. Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report.
    Hanna RM; Selamet U; Hasnain H; El-Masry M; Saab S; Wallace WD; Yanny B; Wilson J
    Transplant Proc; 2018 Dec; 50(10):4033-4037. PubMed ID: 30577309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.
    Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y
    BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
    Costero O; Picazo ML; Zamora P; Romero S; Martinez-Ara J; Selgas R
    Nephrol Dial Transplant; 2010 Mar; 25(3):1001-3. PubMed ID: 20019017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Report in the Literature of Biopsy-Proven Noncollapsing Focal Segmental Glomerulosclerosis Relapse in a Second Renal Transplant Presenting With Thrombotic Microangiopathy: A Case Report.
    Rosa-Guerrero P; Leiva-Cepas F; Agüera-Morales M; Navarro-Cabello MD; Rodríguez-Benot A; Torres-De-Rueda A
    Transplant Proc; 2021 Nov; 53(9):2747-2750. PubMed ID: 34627595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Staufer K; Fischer L; Seegers B; Vettorazzi E; Nashan B; Sterneck M
    Transpl Int; 2012 Nov; 25(11):1158-64. PubMed ID: 22882364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
    Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
    Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
    Takahara T; Nitta H; Hasegawa Y; Itou N; Takahashi M; Wakabayashi G
    Transplant Proc; 2011 Sep; 43(7):2800-5. PubMed ID: 21911167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
    Cortina G; Trojer R; Waldegger S; Schneeberger S; Gut N; Hofer J
    Pediatr Nephrol; 2015 Apr; 30(4):693-7. PubMed ID: 25577332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.
    Inoue D; Nishi H; Honda K; Ishii T; Abe H; Sato M; Nangaku M
    Clin Nephrol; 2020 Jan; 93(1):47-50. PubMed ID: 31699213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney.
    Buob D; Decambron M; Gnemmi V; Frimat M; Hoffmann M; Azar R; Gheerbrant JD; Guincestre T; Noël C; Copin MC; Glowacki F
    Kidney Int; 2016 Dec; 90(6):1321-1331. PubMed ID: 27650730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.
    Java A; Edwards A; Rossi A; Pandey R; Gaut J; Delos Santos R; Miller B; Klein C; Brennan D
    Transpl Int; 2015 Sep; 28(9):1121-5. PubMed ID: 25864519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
    Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
    Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
    Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
    Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
    Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children.
    Dall'Amico R; Ghiggeri G; Carraro M; Artero M; Ghio L; Zamorani E; Zennaro C; Basile G; Montini G; Rivabella L; Cardillo M; Scalamogna M; Ginevri F
    Am J Kidney Dis; 1999 Dec; 34(6):1048-55. PubMed ID: 10585314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.
    Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW
    Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.